Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin/Loteprednol Fixed Combination vs Individual Administration for Ocular Infections
NCT01721694Phase 3Withdrawn
- Sponsor
- Adapt
- Start
- Dec 2012
- Primary completion
- Mar 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azithromycin and loteprednol etabonate in Bacterial blepharitis, bacterial keratitis, bacterial conjunctivitis (BC) and 1 more (2 arms), sponsored by Adapt. Primary endpoint: Clinical cure at Day 8. Planned start Dec 2012; status: withdrawn.
02
Drugs
azithromycinloteprednol etabonate
03
Conditions
Bacterial blepharitisbacterial keratitisbacterial conjunctivitis (BC)ocular inflammation
Beyond the preview
Go deeper on NCT01721694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721694.